Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Mark E. Potter; Edward E. Partridge; Hugh M. Shingleton; Seng Jaw Soong; Robert Y. Kim; Kenneth D. Hatch; J. Maxwell Austin

doi:10.1016/0090-8258(89)90631-8

Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Mark E. Potter, Edward E. Partridge, Hugh M. Shingleton, Seng Jaw Soong, Robert Y. Kim, Kenneth D. Hatch, J. Maxwell Austin

Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

Original language	English (US)
Pages (from-to)	314-318
Number of pages	5
Journal	Gynecologic oncology
Volume	32
Issue number	3
DOIs	https://doi.org/10.1016/0090-8258(89)90631-8
State	Published - Mar 1989

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/0090-8258(89)90631-8

Cite this

@article{d45cdea5ea3341a48ee86746813ca4be,

title = "Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits",

abstract = "Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated {"}secondarily{"} after tumor recurrence or after a {"}positive{"} second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in {"}secondary{"} therapy of advanced stage and grade tumors.",

author = "Potter, {Mark E.} and Partridge, {Edward E.} and Shingleton, {Hugh M.} and Soong, {Seng Jaw} and Kim, {Robert Y.} and Hatch, {Kenneth D.} and Austin, {J. Maxwell}",

year = "1989",

month = mar,

doi = "10.1016/0090-8258(89)90631-8",

language = "English (US)",

volume = "32",

pages = "314--318",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Intraperitoneal chromic phosphate in ovarian cancer

T2 - Risks and benefits

AU - Potter, Mark E.

AU - Partridge, Edward E.

AU - Shingleton, Hugh M.

AU - Soong, Seng Jaw

AU - Kim, Robert Y.

AU - Hatch, Kenneth D.

AU - Austin, J. Maxwell

PY - 1989/3

Y1 - 1989/3

N2 - Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

AB - Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

UR - http://www.scopus.com/inward/record.url?scp=0024561357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024561357&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(89)90631-8

DO - 10.1016/0090-8258(89)90631-8

M3 - Article

C2 - 2920951

AN - SCOPUS:0024561357

SN - 0090-8258

VL - 32

SP - 314

EP - 318

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this